drugset / Trial / NCT05265975
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
NaSingle-groupOpen-labelTreatment
Summary
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (A SCT).
Timeline
- Start
- 2022-04-07
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | — |
| Subject | Selinexor | Other / unclassified | 60 mg | — |
| Subject | Selinexor | Other / unclassified | 80 mg | — |
| Background | Lenalidomide | Other / unclassified | — | Oral |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |